A Phase III Study to Assess the Efficacy and Safety of GV1001-Gem/Cap vs Gem/Cap in Pancreatic Cancer Patients
Status:
Unknown status
Trial end date:
2018-05-01
Target enrollment:
Participant gender:
Summary
To assess treatment of GV1001 concurrent with Gemcitabine/Capecitabine versus
Gemcitabine/Capecitabine alone in locally advanced and metastatic pancreatic cancer patients.